Here, thermo-responsive liposomes were investigated for their potential to actively control the release of teriparatide after subcutaneous administration. At first, different entrapment methods were explored to identify the most suitable approach to maximise peptide loading within the liposomes. Initially, a once weekly formulation was desired, providing 7 individual doses of teriparatide (20 -40 µg/dose) . To achieve this, the liposomal formulation must contain a minimum of 140 -280 µg of teriparatide. The liposome composition was optimised to achieve a target transition temperature of 43 -45 °C and the temperature-dependant release of pharmacologically active teriparatide confirmed using a cell-based PTH1R receptor binding assay.